# MOTS-c peptide FAQ: Side Effects, Safety, and Common Questions > MOTS-c peptide FAQ: side effects and safety context, weight and liver questions, timelines, and what the research does and does not establish. Cited where quantitative. Direct, cited answers to the questions people ask about MOTS-c — safety, side effects, timelines, and the boundary between research findings and human outcomes. ## What are the negative side effects of MOTS-c? There are no completed human safety trials of exogenous MOTS-c, so a human side-effect profile has not been established. The published evidence base is animal and observational, and product purity and sterility are not regulated as pharmaceuticals. Any specific human side-effect claim would go beyond the available evidence. ## What are the downsides of MOTS-c? The main limitations are evidentiary: no human efficacy trials, no validated human pharmacokinetics, unregulated research-chemical sourcing, and an anti-doping prohibition for athletes. Consumer interest in fat loss, longevity, and performance currently outpaces the strength of the clinical evidence [1][2]. That gap is the principal downside this digest exists to make clear. ## Can MOTS-c cause weight gain? In animal models MOTS-c reduced diet-induced obesity and improved metabolic homeostasis rather than promoting weight gain [1]. No human interventional weight data exist, so a weight-gain effect in people cannot be characterised from the literature. ## Does MOTS-c burn fat? In mice, MOTS-c reduced diet-induced obesity and increased adipose thermogenic activation, and it improved insulin sensitivity and reshaped the plasma metabolome [1]. There are no human fat-loss trial results, so "burns fat" is a rodent finding, not a demonstrated human outcome. ## Is MOTS-c hard on the liver? No published human hepatotoxicity data exist, because no human safety trials have been completed. Statements about organ effects in humans would go beyond the available preclinical and observational evidence. The literature does not support specific claims of liver harm or liver benefit in people. ## Is MOTS-c bad for the liver? No human liver-safety data exist for exogenous MOTS-c. The peer-reviewed literature does not support specific claims about liver harm or benefit in humans; the human evidence base is biomarker associations, not interventional safety data. ## How does MOTS-c make you feel? Subjective human experience cannot be characterised from the literature, because no completed human interventional trials report patient-reported outcomes. The existing human data are biomarker associations only — measurements of endogenous MOTS-c, not reports from people given the peptide [7][9][14]. ## Can I get MOTS-c over the counter? MOTS-c is not an FDA-approved drug or an approved over-the-counter product; it is sold only for laboratory research. There is no approved indication, formulation, or dose, and no over-the-counter MOTS-c product exists. See the legal-status page for the FDA and compounding context. ## How long does it take for MOTS-c to kick in? Animal studies report metabolic effects over chronic dosing windows of roughly one to eight weeks [1]. No validated human onset timeline has been published, so a human "time to kick in" cannot be stated from the evidence. ## How long does MOTS-c take to work? In rodent metabolic studies, measurable changes accrued over multi-week dosing of about one to eight weeks [1]. There is no validated human time-to-effect; the question has only been answered in animals, not people. ## How often do you inject MOTS-c? Published rodent work used daily or thrice-weekly intraperitoneal injection — for example 15 mg/kg/day or 15 mg/kg three times weekly in aged mice [2]. There is no validated human dosing frequency; these are laboratory regimens in animals, not human guidance. ## Can I inject MOTS-c every day? Both daily and thrice-weekly intraperitoneal regimens appear in rodent studies, with no consensus optimal frequency [1][2]. There is no validated human schedule, and MOTS-c is not an approved drug for human use. ## Where is best to inject MOTS-c? Rodent studies overwhelmingly used intraperitoneal injection, with subcutaneous injection in some research contexts [1][2]. These are laboratory routes in animals, not human administration guidance, and no human injection-site protocol exists in the literature. ## How long should you take MOTS-c? Published animal studies ran from about one week (acute) to roughly twelve weeks (chronic, such as bone studies) [1]. No human cycle length has been established, so a recommended human duration cannot be drawn from the evidence. ## What are the top peptides for muscle growth? MOTS-c is studied for muscle homeostasis — reducing myostatin and atrophy signalling and acting via CK2 — rather than as a hypertrophy agent [2][13]. This digest covers MOTS-c only and does not rank or recommend other peptides for muscle growth. ## What does the MOTS-c peptide do? MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It inhibits the folate cycle and de novo purine biosynthesis, raising AICAR and activating AMPK, which improves glucose handling and insulin sensitivity in skeletal muscle in animal models [1][4]. ## What are the potential benefits of MOTS-c? Animal and observational research describe improved insulin sensitivity, reduced diet-induced obesity, enhanced physical capacity, and roles in stress-adaptive and aging pathways [1][2][4]. These are research findings, not demonstrated human outcomes; no human efficacy trial has confirmed them. ## Has MOTS-c been studied for memory or brain health? Yes, in early work. A cell-penetrating MOTS-c analogue enhanced memory and attenuated amyloid-beta(1-42)- or LPS-induced memory impairment by inhibiting neuroinflammation in mice [5]. In humans, serum MOTS-c differed between multiple sclerosis patients and controls [6]. All neuro evidence is preclinical or observational. ## Is MOTS-c legal to buy? MOTS-c is not approved by the FDA for human use and is sold only as a research chemical for laboratory use. It is treated as a prohibited substance in elite sport, and legal status for purchase varies by jurisdiction. See the legal-status page for the FDA 503A and PCAC context. ## Can you get MOTS-c from a compounding pharmacy? Whether a 503A pharmacy may compound a given ingredient depends on that ingredient's eligibility under the FD&C Act. MOTS-c is not on a final bulks list; it is scheduled for FDA PCAC evaluation on July 23-24, 2026, which is a step in evaluation, not eligibility for routine compounding. A valid prescription and prescriber evaluation are also required. ## What is the FDA 503A status of MOTS-c? MOTS-c is a research peptide, not an FDA-approved drug, scheduled for PCAC evaluation as a candidate for the 503A bulks list at the July 23-24, 2026 meeting. This digest does not assign it a numbered 503A category; "under evaluation" is distinct from being on the bulks list or approved for compounding. ## Is MOTS-c legal? MOTS-c is research-only and not FDA-approved for human use. It is individually named on the FDA PCAC agenda for July 23-24, 2026 for evaluation as a possible 503A bulks-list substance — a scheduled discussion, not a decision. Sport-governing bodies treat it as prohibited, and purchase legality varies by jurisdiction. --- A flat-laid specimen catalogue of the MOTS-c research record — each study, dose figure, and access fact logged to source and tagged by evidence strength, the human-data gaps left in plain view; no clinic behind the tray and nothing here dispensed or sold.